{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.0","upperLimit":"23.0","value":"21.5"},{"groupId":"OG001","lowerLimit":"36.0","upperLimit":"44.0","value":"39.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Time to CHR is the time (in days) from first dose of dasatinib until the first day CHR criteria were met, provided they were confirmed later after 28 days with no concomitant use of anagrelide or hydroxyurea during this interval. Refer to Outcome Measure 16 for criteria to CHR in Stratum 1 and to Outcome Measure 15 for criteria for CHR in Stratum 2/3. Estimated by the Kaplan-Meier method and a 2-sided 95% CI for median was computed using the Brookmeyer and Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose"}],"paramType":"MEDIAN","populationDescription":"All treated participants with CHR in strata 1 and 2/3.","reportingStatus":"POSTED","timeFrame":"Days 8, 15, 22, 29, 36, 43; Weeks 7, 13, 25, 37; at Week 4, 19, 31 (only stratum 2/3); then every 12 weeks upto 24 months; then once/year; until criteria was first met for CHR (maximum participant time to first CHR of 65 days).","title":"Time to Complete Hematologic Response (CHR): Stratum 1 (Ph+ CP-CML) and Stratum 2/3 (Ph+ALL or AP/BP-CML)","type":"SECONDARY","unitOfMeasure":"days"}